Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could allow competitors to gain ground, weaken pricing power and slow earnings growth
SENSEX 77,321.54
+ 579.72
NIFTY 24,123.65
+ 160.85
CRUDEOIL 6,914.00
Citi retains its sell call with a target price of ₹1,040, and BofA retains its accumulate recommendation with a target price of…
Dr Reddys shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69%…
Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product…
Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a…
Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and…
Aurobindo Pharma surpasses Dr Reddy's in FY26 revenue, becoming the second-largest Indian pharma company.
